


Revenue	GAAP diluted EPS	Non- GAAP diluted EPS
\$9.8B	\$1.14	\$1.45
+13.7% reported +13.7% organic	+40.7% Y/Y	+15.1% Y/Y

Revenue by business

Cardiovascular \$3.9B +18.9% Y/Y Organic	Neuroscience \$2.7B +9.3% Y/Y Organic
Medical Surgical \$2.3B +10.2% Y/Y Organic	Diabetes \$843M +14.9% Y/Y Organic

Revenue by geography

United States	International
\$4.9B	\$4.9B
+15.8% Y/Y Organic	+11.6% Y/Y Organic



//

We are off to a strong start in fiscal 2027. What gives us confidence is not simply the strength of the quarter, but importantly, the breadth of performance across our businesses and the increasing contributions from newer growth platforms. Our execution, alongside our innovation engine, positions us to serve more patients and deliver durable growth. The strength of our portfolio and pipeline gives us confidence in the opportunities ahead."

Geoff Martha,
Chairman & CEO

